Fantastic talk by Toni Choueiri at ESMO2024 on Ti-Nivo2 trial

Petros Grivas shared a post by Yüksel Ürün on X, adding:

“Fantastic talk by brilliant Toni Choueiri from Dana-Farber Center for Genitourinary Oncology,Dana-Farber Cancer Institute, at ESMO2024 on Ti-Nivo2 trial!

Second trial after Contact03 with NO benefit with ICI rechallenge in mRCC!”

Quoting Yüksel Ürün:

“A critical question on the sequential use of therapies in renal cancer addressed!

Huge congratulations to Toni Choueiri and the team for the TiNivo-2 study findings.”

Source: Petros Grivas/X and Yuksel Urun/X

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.